Percutaneous fetal cardiac interventions for structural heart disease

Percutaneous fetal cardiac interventions for structural heart disease.

Schidlow DN, Tworetzky W, Wilkins-Haug LE.

Am J Perinatol. 2014 Aug;31(7):629-36. doi: 10.1055/s-0034-1383884. Epub 2014 Jun 12.

PMID: 24922056 [PubMed – in process]

Related citations

Select item 24858853

Comment from Dr. Mehul Patel, editor of Congenital Heart Journal Watch: This review summaries the utility of percutaneous FCI in:

(1) Aortic stenosis with evolving hypoplastic left heart syndrome, for which aortic valvuloplasty may prevent left ventricular hypoplasia and has yielded a biventricular circulation in approximately one third of cases.

(2) Hypoplastic left heart syndrome with intact atrial septum, for which relief of atrial restriction has potential to improve perinatal survival; and

(3) Pulmonary atresia with intact ventricular septum and evolving right ventricular hypoplasia, for which pulmonary valvuloplasty has resulted in a biventricular circulation in the majority of patients. The pathophysiology, rationale for intervention, patient selection criteria, procedural technique, outcomes and complications for each lesion is reviewed.

( average: 5.00 )
Loading...Loading...

A novel design biodegradable stent for use in congenital heart disease: Mid term results in rabbit descending aorta

“A novel design biodegradable stent for use in congenital heart disease: Mid term results in rabbit descending aorta”

Veeram Reddy SR, Welch TR, Wang J, Richardson JA, Forbess JM, Riegel M, Nugent AW.

Catheter Cardiovasc Interv. 2014 Aug 26. doi: 10.1002/ccd.25648. [Epub ahead of print]

PMID: 25157439 [PubMed – as supplied by publisher]

Related citations

Select item 25156919

Comment from Dr. Mehul Patel, editor of Congenital Heart Journal Watch: This well designed pilot study confirms the feasibility of delivery and deployment of up to 6-millimeter diameter double-opposing helical (DH) poly-l-lactic acid biodegradable stent (BDS) in rabbit descending aorta (DAO). Stent integrity with DH design was maintained at 9 months with minimal vessel inflammation. Potential morbidity due to embolized BD fragments cannot be ruled out and needs further evaluation.

08 2014 pic 3

( average: 5.00 )
Loading...Loading...